Incretin hormone agonists as promising antiobesity drugs - review of literature
DOI:
https://doi.org/10.12775/JEHS.2025.77.56677Keywords
obesity, antiobesity drugs, glucagon like peptide-1, glucose-dependent insulinotropic polypeptide, incretin hormone agonistsAbstract
The aim of this work is to draw attention to the recently growing problem of obesity and complications related to it. Dietary recommendations and recommendations regarding physical activity turned out not to show satisfactory effects in patients with obesity in terms of weight loss, but also in maintaining the effects of the actions taken. The basic basis of the problem turned out to be much more complicated. It is not only related to the occurrence of a positive energy balance, but also to the dysfunction of the entire organism. The discovery of incretin hormones and their complex mechanism of action gave a new direction to the treatment of metabolic diseases. The drugs presented below act on the incretin receptor, stimulating it and causing an effect that leads to weight loss.
References
Alhomoud IS, Talasaz AH, Chandrasekaran P, et al. Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management. Pharmacotherapy. 2024 Sep;44(9):738-752.
Mayoral LP, Andrade GM, Mayoral EP, et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res. 2020 Jan;151(1):11-21.
Romieu I, Dossus L, Barquera S, et al. Energy balance and obesity: what are the main drivers? Cancer Causes Control. 2017 Mar;28(3):247-258.
DiPatrizio NV. Endocannabinoids and the Gut-Brain Control of Food Intake and Obesity. Nutrients. 2021 Apr 7;13(4):1214.
Crouch M, Al-Shaer A, Shaikh SR. Hormonal Dysregulation and Unbalanced Specialized Pro-Resolving Mediator Biosynthesis Contribute toward Impaired B Cell Outcomes in Obesity. Mol Nutr Food Res. 2021 Jan;65(1):e1900924.
Marcelin G, Silveira ALM, Martins LB, et al. Deciphering the cellular interplays underlying obesity-induced adipose tissue fibrosis. J Clin Invest. 2019 Oct 1;129(10):4032-4040.
Okifuji A, Hare BD. The association between chronic pain and obesity. J Pain Res. 2015 Jul 14;8:399-408.
Grill HJ. A Role for GLP-1 in Treating Hyperphagia and Obesity. Endocrinology. 2020 Aug 1;161(8):bqaa093.
Nimptsch K, Konigorski S, Pischon T. Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine. Metabolism. 2019 Mar;92:61-70.
Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. Obesity Management in Adults: A Review. JAMA. 2023 Nov 28;330(20):2000-2015.
Holst JJ. From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy. Front Endocrinol (Lausanne). 2019 Apr 26;10:260.
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. [13] Zhao X, Wang M, Wen Z, et al. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne). 2021 Aug 23;12:721135.
De Graaf C, Donnelly D, Wootten D, et al. Pharmacological Reviews. 2016 Oct 1;68(4):954-1013.
De Graaf C, Donnelly D, Wootten D, et al. Pharmacological Reviews. 2016 Oct 1;68(4):954-1013.
Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/
Gasbjerg LS, Gabe MBN, Hartmann B, et al. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides. 2018 Feb;100:173-181.
Holst JJ, Rosenkilde MM. GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists. J Clin Endocrinol Metab. 2020 Aug 1;105(8):e2710–6.
Gault VA, O'Harte FP, Flatt PR. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides. 2003 Oct;37(5):253-63.
Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 2021 Apr 6;33(4):833-844.e5.
Muto A, Lal P, Ailani D, et al. Activation of the hypothalamic feeding centre upon visual prey detection. Nat Commun. 2017 Apr 20;8:15029.
Cerillo JL, Parmar M. Liraglutide. [Updated 2024 Oct 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK608007/
Elkind-Hirsch KE, Chappell N, Shaler D, et al. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertility and Sterility, 2022 Aug; 118(2): 371 - 381.
Seo YG. Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes. J Obes Metab Syndr. 2021 Mar 30;30(1):12-19.
Muñoz MPS, Blandón JDR, Gutierrez ISC, et al. Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery. Updates Surg. 2024 Oct;76(6):2277-2283.
Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022 Mar;57:101351.
Diene G, Angulo M, Hale PM, et al. Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity. J Clin Endocrinol Metab. 2022 Dec 17;108(1):4-12.
Besemer F, Verschoor AJ, Diamant M, et al. Vesiculopustular dermatosis: an uncommon side-effect of liraglutide? J Diabetes Complications. 2012 Sep-Oct;26(5):458-9.
Yu J, Lee J, Lee SH, et al. A Study on Weight Loss Cause as per the Side Effect of Liraglutide. Cardiovasc Ther. 2022 Dec 2;2022:5201684.
Kommu S, Whitfield P. Semaglutide. [Updated 2024 Feb 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK603723/
Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024 Jul;30(7):2049-2057.
Bergmann NC, Davies MJ, Lingvay I, et al. Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obes Metab. 2023 Jan;25(1):18-35.
Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023 Apr;33(3):159-166.
Wilding JPH, Batterham RL, Calanna S, et al. STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002.
Murvelashvili N, Xie L, Schellinger JN, Met al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity (Silver Spring). 2023 May;31(5):1280-1289.
Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563. Erratum in: Front Endocrinol (Lausanne). 2021 Nov 10;12:786732.
Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 26;402(10403):705-719.
Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):138-150.
Azuri J, Hammerman A, Aboalhasan E, et al. Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis. Obesity (Silver Spring). 2023 Jun;31(6):1510-1513. [40] Xie Z, Yang S, Deng W, et al. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review. Clin Epidemiol. 2022 Dec 6;14:1463-1476.
Farzam K, Patel P. Tirzepatide. 2024 Feb 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 36251836.
Baker DE, Walley K, Levien TL. Tirzepatide. Hosp Pharm. 2023 Jun;58(3):227-243.
Zandvakili I, Perez-Tilve D. The unexpected role of GIP in transforming obesity treatment. Trends Endocrinol Metab. 2024 Aug 27:S1043-2760(24)00217-0.
le Roux CW, Hankosky ER, Wang D, et al. Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison. Diabetes Obes Metab. 2023 Sep;25(9):2626-2633.
Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024 Sep 1;184(9):1056-1064.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216.
Andraos J, Muhar H, Smith SR. Beyond glycemia: Comparing tirzepatide to GLP-1 analogues. Rev Endocr Metab Disord. 2023 Dec;24(6):1089-1101.
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024 Jan 2;331(1):38-48.
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515.
Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 Aug;65(8):1251-1261.
Reitzel SB, Bøgelund M, Basse A, et al. Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates. Curr Med Res Opin. 2023 Aug;39(8):1055-1060.
Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023 Dec 14;14(1):8289.
Zhang B, Cheng Z, Chen J, et al. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care. 2024 Jan 1;47(1):160-168.
Nalisa DL, Cuboia N, Dyab E, et al. Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2024 Feb 14;15:1309118.
Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023 Aug 12;402(10401):529-544.
Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024 Jul;30(7):2037-2048.
Pasqualotto E, Ferreira ROM, Chavez MP, et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabol Open. 2024 Sep 13;24:100321.
Asadi A, Shadab Mehr N, Mohamadi MH, et al. Obesity and gut-microbiota-brain axis: A narrative review. J Clin Lab Anal. 2022 May;36(5):e24420.
Christensen S, Robinson K, Thomas S, et al. Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs. Obes Pillars. 2024 Jul 25;11:100121.
Yazıcı D, Yapıcı Eser H, et al. Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity. Obes Facts. 2023;16(2):149-163.
Nagi MA, Ahmed H, Rezq MAA, et al. Economic costs of obesity: a systematic review. Int J Obes (Lond). 2024 Jan;48(1):33-43.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Aleksandra Grzegorczyk, Justyna Korus, Marta Dziedziak, Nicol Dardzińska, Natalia Hopej
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 66
Number of citations: 0
